

“Hot and Sweaty” When is it Menopause?

DR NICOLE AVARD



NEXT PRACTICE
A NEW KIND

- ▶ Acknowledgement of country
- ▶ Women – assigned female at birth (AFAB)



NEXT PRACTICE
A NEW KIND

Overview

- ▶ What is Menopause and do you diagnose it?
- ▶ What are the common symptoms?
- ▶ Why does it matter?
- ▶ How to approach the consultation
- ▶ What other preventative impacts do we need to think about?
- ▶ Approach to treatment



NEXT PRACTICE
A NEW KIND

Your Turn

- ▶ Menopause is....
- ▶ One day in the life of a women
- ▶ 12 months after the cessation of her Menstrual cycle
- ▶ Unless it is surgical menopause or iatrogenic
- ▶ Perimenopause – 4-7 years prior to the cessation of the period
- ▶ Hysterectomy/ablation



What are the common symptoms ?

- ▶ Physical
- ▶ Psychological
- ▶ Those not spoken about

- ▶ Average age 51
- ▶ Under 40 – Premature Ovarian Insufficiency
- ▶ 40-45- early menopause /POI - a note on stress



Physical

- ▶ Changes on Menstrual Cycle – Investigation of irregular PV bleeding
- ▶ Sleep disturbance
- ▶ Hot flushing
- ▶ Weight gain
- ▶ Dry skin, eyes, formication
- ▶ Hair loss
- ▶ Bloating



Psychological

- ▶ Low mood/depression-high divorce and suicide rates
- ▶ Irritability
- ▶ Rage
- ▶ Anxiety
- ▶ Brain fog and difficulty concentrating



NEXT PRACTICE
A NEW KIND

Those not spoken about

- ▶ Vaginal dryness (Vulval conditions lichen sclerosis, psoriasis, dermatitis)
- ▶ Urinary frequency
- ▶ Urinary tract infections
- ▶ Painful intercourse
- ▶ Low libido



NEXT PRACTICE
A NEW KIND

Why does it matter?

- ▶ 100 % women
- ▶ 20% no symptoms
- ▶ 60% mild to moderate symptoms
- ▶ 20% severe
- ▶ 1 million women
- ▶ 25% less likely to take on leadership roles or reduce hours
- ▶ 40% more sick leave
- ▶ 10% leave the workforce
- ▶ \$112 billion dollars



NEXT PRACTICE
A NEW KIND

Approach to the consultation

► History – Physical

Menstrual cycle, IMB, PCB

Heavy Menstrual bleeding

Hot flushing

Pre -menstrual symptoms eg breast tenderness, migraine,

Dysmenorrhoea

Sleep

Changes in weight

Dry skin and hair/hair loss , dry eyes

Bloating – take care with ovarian cancer

Joint pain



NEXT PRACTICE
A NEW KIND

Approach to the consultation cont...

► Psychosocial

Description of mood esp depression (Meno-D)

Anxiety (DASS-21)

Irritability and rage

Emotional lability

Impact on work

Impact on family and other relationships

Smoking

Alcohol intake

Dietary intake and exercise



NEXT PRACTICE
A NEW KIND

Approach to the consultation cont...

Those not spoken about...

Urinary symptoms- frequency, recurrent UTI's

Vaginal dryness or irritation

Urgency and stress incontinence

Low libido

Painful intercourse

Intimacy , pleasure



NEXT PRACTICE
A NEW KIND

Preventative Health

- ▶ Peri Menopause and Menopause is the gateway to increased of chronic disease including Cardiovascular events, Osteoporosis, Breast cancer and Dementia
- ▶ Family History
- ▶ CST
- ▶ Mammogram
- ▶ Bone density if indicated

www.garvan.org.au/research/bone-fracture-risk-calculator

- ▶ CV risk assessment

www.cvdcheck.org.au

- ▶ Sleep apnoea screen (STOPBANG)
- ▶ CONTRACEPTION- 2 years after the last cycle if under 50 and 1 year after the last cycle if > 50.



NEXT PRACTICE
A NEW KIND

Screening for women with low bone density

CONVENTIONAL RISK FACTORS FOR OSTEOPOROSIS AND FRACTURE

- Previous fracture
- Glucocorticoid therapy
- Parental history of hip fracture
- Low body weight
- Current smoker
- Excessive alcohol consumption
- Rheumatoid Arthritis
- Secondary causes (e.g. POI, medicines)

RELEVANCE IN YOUNGER WOMEN



- Presence of risk factors increases the chance of
 - low peak bone mass
 - premenopausal bone loss

Examination

- ▶ Height weight blood pressure
- ▶ Breast examination
- ▶ Abdominal examination
- ▶ PV- Labial and vulval changes, allodynia , cystocele, rectocele, Spec examantion
- ▶ CST if applicable with PV palpation



NEXT PRACTICE
A NEW KIND

Diagnosis

- ▶ CLINICALLY
- ▶ FSH when ? < 40, 40-45 with irregular cycle possibly, Ablation, hysterectomy
- ▶ >25 6 weeks apart
- ▶ TSH and Iron studies
- ▶ Lipids and fasting BSL +/- HBA1c or OGTT (PCOS)
- ▶ Pelvic U/S – diagnosis of IMB or menorrhagia , consideration for ovarian cancer



What do we do

- ▶ Patient education – Australian Menopause Society Patient Information

www.menopause.org.au/hp/information-sheets

- ▶ Lifestyle measures and risk reduction measures
- ▶ MHT
- ▶ Non hormonal therapies



NEXT PRACTICE
A NEW KIND

Lifestyle and Allied Interventions

Find the choice point

- ▶ Smoking cessation
- ▶ ETOH reduction
- ▶ Diet- reduce refine CHO, increase protein, serving sizes, caloric need, calcium intake (dairy products, fish with bones, sesame seeds)
- ▶ Hot flushing- reduce caffeine, light cotton clothing, reduce spices, layers
- ▶ Movement- cardio and weight bearing , morning exercise
- ▶ Sleep hygiene- phones and screen, layers , room temperature , mediation
- ▶ Stress management - time in nature, box breathing, psychological intervention
- ▶ CBT and MBSR
- ▶ Pelvic Floor physiotherapy



NEXT PRACTICE
A NEW KIND

What about MHT???

Far and away the most effective way to assist with symptom reduction

- ▶ Women's Health Initiative
- ▶ If started before age 60 reduction in cardiovascular events and bone protection
- ▶ Improved all cause mortality and reduced fracture risk
- ▶ Breast cancer risk 1:1000 - 14:1000 depending on age. Population risk 1:8

<https://www.petermac.org/iprevent>

- ▶ Increased risk VTE 2:1000 depending on delivery
- ▶ Recent Dementia study taken with care



NEXT PRACTICE
A NEW KIND

WHI: What It Got Right, What It Got Wrong

Inappropriate generalization
 Failure to adequately acknowledge
 Claims of harm unsupported




Condition	RIGHT	WRONG
Age	No benefit at older ages	Generalized that to younger ages
CHD	No benefit at older ages Progestogen modulates the effect Prompted timing hypothesis	Generalized that to younger ages Failed to publish that fact Failed to acknowledge the timing effect
Breast Cancer	Progestogen modulates the effect Lower breast cancer (benefit) with CEE-Alone	Published breast cancer harm when it was not statistically significant Failed to publish that fact Failed to properly acknowledge that fact
Fracture	Benefit with all regimens Benefit regardless of age	
Cognitive	Harm if started at older ages Lower dementia mortality in followup	Generalized that to younger ages Failed to note that timing hypothesis applies Failed to note that
All Cause Mortality	No benefit at older ages	Did not clearly state benefit at younger ages Failed to note that fact
Regimens	Found opposing outcomes for CEE-Alone and CEE+MPA	Generalized CEE+MPA to all HRT The for shortest duration is contrary to results Suggested use of lowest dose when only one dose was tested

What about MHT???



Breast Cancer risk in UK women aged 50-59:



What about MHT???


Risks and benefits of MHT between 50-59 yrs or <10 yr after menopause

REC



B

- Fractures
- Diabetes
- Breast cancer
- Colorectal cancer
- Overall mortality
- Coronary heart disease
- Endometrial cancer
- Lung cancer
- Venothrombotic episodes
- Stroke
- Cholecystitis



Santen R J et al. JCEM 2010;95:s1-s66

©2010 by Endocrine Society

THE JOURNAL OF
CLINICAL
ENDOCRINOLOGY
& METABOLISM



NEXT PRACTICE
A NEW KIND

Contraindications to MHT

- ▶ Undiagnosed vaginal bleeding
- ▶ Active Cardiovascular disease
- ▶ Active or past history of hormone sensitive cancer
- ▶ Previous VTE – liase with haematologist
- ▶ Intolerance or patient preference



NEXT PRACTICE
A NEW KIND

How to deliver MHT

- ▶ Tablets
- ▶ Patches
- ▶ Gels
- ▶ Vaginal pessaries
- ▶ Patient preference and cost
- ▶ **Cyclical** = Oestrogen given continuously with Progesterone 14 days of 28. Can induce a withdrawal bleed. Usually how it is delivered within 12 months of the cycle ceasing
- ▶ **Continuous**= Oestrogen and progesterone continuously. Usually after 12 months of amenorrhoea.
- ▶ Progesterone **MUST** be given in adequate doses to all women with a uterus using oestrogen (aside vaginal delivery) to protect against endometrial cancer



How to deliver MHT

- ▶ Oestrogen

- ▶ Oestradiol tablets 1-3mg
- ▶ Oestradiol Gel 75mcg/pump 1-3 pumps
- ▶ Oestradiol patch 50mcg-100mcg
- ▶ Oestradiol pessaries for GSM symptoms 10 mcg

- ▶ Progesterone

- ▶ MPA 2.5-10mg
- ▶ Norethisterone 1.25-2.5 mg
- ▶ Dydrogesterone (anti And Anti Min) 5-10mg
- ▶ Drospirinone 1-2 mg
- ▶ Micronised Progesterone 100-200mg

- ▶ LARC as a progesterone options

- ▶ Mirena



NEXT PRACTICE
A NEW KIND

AMS Guide to Equivalent MHT/HRT Doses

AUSTRALIA ONLY

This Information Sheet has been developed as a guideline only to approximately equivalent doses of the different TGA registered MHT/HRT products available in Australia in August 2022. Hormone Replacement Therapy (HRT) is now referred to as Menopausal Hormone Therapy (MHT). The intention of this sheet is to help physicians change their patients to higher or lower approximate doses of MHT if needing to tailor therapy, or remain within the same approximate dose if needing to change brands of MHT. Private/non-PBS script products are marked with an*

CYCLIC MENOPAUSAL HORMONE THERAPY (MHT)

Use continuous oestrogen and cyclic progestogen combinations at peri-menopause or if less than 12 months amenorrhoea

LOW DOSE		
PRODUCT	PRESENTATION	COMPOSITION
Femoston	tablet	1mg oestradiol/10mg dydrogesterone
Estrogel Pro*	Combination pack of oestradiol transdermal gel, with micronised progesterone capsules.	1 pump (0.75mg oestradiol) daily, and 2 capsules (200mg) micronised progesterone orally for 12 days out of a 28-day cycle
MEDIUM DOSE		
Trisequens*	tablet	1 and 2mg oestradiol/1mg norethisterone
Femoston	tablet	2mg oestradiol/10mg dydrogesterone
Estalis sequi 50/140)	transdermal patch	50mcg oestradiol/140mcg norethisterone acetate (twice weekly application)
Estalis sequi 50/250 (same oestrogen, more progestogen than Estalis sequi 50/140)	transdermal patch	50mcg oestradiol/250mcg norethisterone acetate (twice weekly application)
Estrogel Pro*	Combination pack of oestradiol transdermal gel, with micronised progesterone capsules.	2 pumps (1.5mg oestradiol) daily, and 2 capsules (200mg) micronised progesterone orally for 12 days out of a 28-day cycle

<https://www.menopause.org.au/hp/information-sheets/ams-guide-to-mht-hrt-doses>



NEXT PRACTICE
A NEW KIND

Choice of progestogen for endometrial protection

Progestogen	"LOW DOSE" 1 pump of E2 gel 25ug patch 1mg E2 tablet CE 0.3mg	"MEDIUM DOSE" 2 pumps of E2 gel 50ug patch 2mg E2 tablet CE 0.625	"HIGH DOSE" 3 pumps of E2 gel 75ug patch
Mic. progesterone Sequential 14 days	200mg daily	200 mg daily	300mg daily
Mic. Progesterone continuous	100mg daily	100 mg daily	200mg daily
Dydrogesterone sequential 14 days	10mg daily	10 mg daily	20mg daily
Dydrogesterone continuous	5mg daily	10 mg daily	20 mg daily
MPA continuous	2.5 – 5mg daily	5 mg daily	10mg daily
NETA continuous	0.5mg daily	1mg daily	2mg daily




Non hormonal options

- ▶ CBT and MBSR especially for sleep
- ▶ Hypnotherapy
- ▶ SSRI/SNRI eg fluoxetine (not with Tamoxifen), Venlafaxine
- ▶ Clonidine
- ▶ Gabapentin
- ▶ Weight Management- peptides
- ▶ New medications coming soon



NEXT PRACTICE
A NEW KIND

VMS - antidepressants vs. other strategies



Pooled analysis from three RCTs including 899 peri- and postmenopausal women with ≥ 14 bothersome VMS's a week.

Interventions:

- escitalopram 10–20 mg/day
- non-aerobic yoga
- aerobic exercise
- 1.8 g/day omega-3 fatty acids
- 0.5-mg/day oral 17-betaE2
- 75-mg/day venlafaxine XR


Guthie KA et al 2015; Obstet Gynecol

Genitourinary symptoms


- ▶ Topical oestradiol for vaginal dryness, recurrent UTI and urge incontinence
- ▶ Pelvic Floor Physiotherapist
- ▶ Pleasure toys and lubricants
- ▶ Mindfulness

Additional Reading


Emily Nagowski- Come as you are



Lori Brotto- Better sex through mindfulness




Dee Hartmann- Pleasure Prescription



What about Ozempic?

High Dose Liraglutide and Semaglutide are the GLP-1 weight loss winners for 2023

Overall efficacy balancing probabilities of achieving highest weight loss relative to probability of experiencing adverse events (SUCRA: surface under the cumulative ranking)



Case Study Tracy 49 y.o female

- ▶ Presents with hot flushes, insomnia, low mood
- ▶ Cycle LMP was 4 months ago
- ▶ No dysmenhorrea , bleed 4 days, no HMB
- ▶ What next ?
- ▶ History
- ▶ Examination
- ▶ Ix
- ▶ Options for treatment

Case Study Leanne 53 y.o female

- ▶ Presents with bloating, hot flushing at night, increased agitation
- ▶ Cycle LMP was just over years ago
- ▶ What next ?

- ▶ History
- ▶ Examination
- ▶ Ix
- ▶ Options for treatment

Useful resources

- ▶ Jean Hailes Institute


www.jeanhailes.org.au/health-a-z/menopause

- ▶ Australian Menopause Society –Patient Handouts

www.menopause.org.au/hp/information-sheets

- ▶ Australian Menopause Society Guide to Menopause

<https://www.menopause.org.au/images/stories/documents/management-menopause-toolkit.pdf>



The image shows the cover of a report titled "A Practitioner's Toolkit for the Management of the Menopause". At the top left is the Monash University logo and name. At the top right is the "M8 Alliance" logo. Below this is a blue banner with the text "Medicine, Nursing and Health Sciences". The main title "A Practitioner's Toolkit for the Management of the Menopause" is in large white font on a dark background. Below the title, it says "Developed by the Women's Health Research Program, School of Public Health and Preventive Medicine, Monash University, 2014". At the bottom, there is a small paragraph of text: "The supporting notes for the Practitioner's Toolkit for Managing the Menopause are published, with free access, in *Climacteric*, the journal of the International Menopause Society. <http://informahealthcare.com/doi/full/10.3109/13697137.2014.929651>

